Daré Bioscience Announces a Poster Presentation on a Pharmacokinetic Study of DARE-FRT1, in Development for Sustained-Release Progesterone Therapy for Pregnancy Maintenance, at the American Society for Reproductive Medicine 2019 Scientific Congress & Expo
Daré’s Chief Scientific Officer,
“The research being highlighted at this year's ASRM meeting reinforces our commitment to develop new treatment options for women at risk for preterm birth and to better support providers and women utilizing progesterone to improve outcomes following an IVF procedure,” said
Impaired fecundity (physical difficulties getting pregnant or carrying a pregnancy to live birth) affects an estimated 6.7 million women aged 15-44 in the U.S., or approximately 11% of women of reproductive age, and 25% of infertile couples have more than one factor leading to infertility.1,2 According to
“DARE-FRT1 has the potential to continuously deliver bio-identical progesterone in a convenient way during a period of 14 days,” said Dr. Friend. “With approximately 10% of all pregnancies in the U.S. resulting in preterm births,4 and the increasing demand for pregnancy support following IVF procedures, DARE-FRT1 could become an important new option for women and healthcare providers seeking better ways to address these significant unmet needs in women’s health.”
Poster Presentation Information
Poster Number: P-173
Abstract Title: 1761: A Novel Progesterone Releasing Intravaginal Ring for Luteal Phase Support: Pharmacokinetics and Safety in a Sheep Model
Session Topic: IVF Outcome Predictors - Luteal Support
1 – Chandra A, et al., Infertility and Impaired Fecundity in
3 – In-Vitro Fertilization (IVF) Market Size, Share & Trends Analysis Report By Type, By Instrument (Disposable Devices, Culture Media, Capital Equipment), By End Use, By Region, And Segment Forecasts, 2019 – 2026,
4 – Martin J, et al., Births: Final Data for 2017, National Vital Statistics Reports, Vol. 67, No. 8,
About Daré Bioscience
Daré Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s health. The company’s mission is to identify, develop and bring to market a diverse portfolio of differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women, primarily in the areas of contraception, vaginal health, sexual health, and fertility.
Daré’s product portfolio includes potential first-in-category candidates in clinical development: Ovaprene®, a hormone-free, monthly contraceptive intravaginal ring; Sildenafil Cream, 3.6%, a novel cream formulation of sildenafil to treat female sexual arousal disorder utilizing the active ingredient in Viagra®; DARE-BV1, a unique hydrogel formulation of clindamycin phosphate 2% to treat bacterial vaginosis via a single application; and DARE-HRT1, a combination bio-identical estradiol and progesterone intravaginal ring for hormone replacement therapy following menopause. To learn more about Daré’s full portfolio of women’s health product candidates, and mission to deliver differentiated therapies for women, please visit www.darebioscience.com.
Daré may announce material information about its finances, product candidates, clinical trials and other matters using its investor relations website (http://ir.darebioscience.com),
Daré cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “plan,” “potential,” “predict,” “seek,” “should,” “would,” “contemplate,” project,” “target,” “tend to,” or the negative version of these words and similar expressions. Such statements include, but are not limited to, statements relating to Daré’s commitment to developing new treatment options for preventing preterm birth and improving outcomes following IVF procedures, DARE-FRT1’s potential to deliver bio-identical progesterone continuously over 14 days in a convenient, non-systemic and non-invasive way, and DARE-FRT1’s potential to prevent preterm birth and support pregnancy maintenance following IVF procedures. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Daré’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, risk and uncertainties related to: Daré’s ability to raise additional capital when and as needed, to advance its product candidates; Daré’s ability to develop, obtain regulatory approval for, and commercialize its product candidates; the failure or delay in starting, conducting and completing clinical trials or obtaining
Investors on behalf of Daré
Media on behalf of Daré
Source: Daré Bioscience
Source: Dare Bioscience, Inc.